VRC-FLUNPF099-00-VP (H1ssF_3928)

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

InfluenzaInfluenza Infection

Phase 1

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

CompletedNCT03814720

National Institute of Allergy and Infectious Diseases (NIAID)Influenza Infection

Start: 2019-04-01End: 2021-04-06Updated: 2022-04-29

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

CompletedNCT05755620

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2023-04-05End: 2025-10-03Updated: 2025-10-31

Related Papers

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

npj Vaccines2024-09-1715 citations

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Science Translational Medicine2023-04-1988 citations

An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans

Science Translational Medicine2023-04-1972 citations

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.

2022-02-03118 citations

Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.

2019-12-0624 citations